Centre conducts clinical trials for PAH treatment

KUCHING: The Sarawak Heart Centre has been chosen as the first site in Malaysia to participate in innovative clinical trials aimed at treating Pulmonary Artery Hypertension (PAH), according to Deputy Premier Datuk Amar Dr Sim Kui Hian.

Dr Sim, who praised the achievement, said that the centre will undergo study of safety and effectiveness of new innovative treatment of patients regarding innovative therapy for the treatment of patients with PAH, a high blood pressure of arteries in the lungs.

“Treatment of PAH, until now, is unsatisfactory with poor prognosis (likely outcome of medical condition), mainly been treated with drugs.

“Thanks to Prof Chen Shao-Liang from Nanjing First Hospital and his team from Pulnovo Medical, HQ Shanghai, invented this new device technology, which could revolutionise the treatment of PAH,” he said in his official Facebook post, recently.

He also said that the remarkable journey and partnership between the two institutions spanned over two decades of delivering clinical service, engaging in postgraduate/proctorship, and advancing with research, global hallmarks of centres of excellence.

“At ground level, the global excellence in healthcare is also grounded in friendship, trust, and professionalism.

“This journey from the heart of China to the heart of Borneo represents a significant milestone in our medical advancements,” Dr. Sim said.